Center-Authored Papers

Filters: Author is Tallman, Martin  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
D
Deininger MW, Kopecky KJ, Radich JP, Kamel-Reid S, Stock W, Paietta E, Emanuel PD, Tallman M, Wadleigh M, Larson RA et al..  2014.  Imatinib 800 mg daily induces deeper molecular responses than imatinib 400 mg daily: results of SWOG S0325, an intergroup randomized PHASE II trial in newly diagnosed chronic phase chronic myeloid leukaemia.. British journal of haematology. 164(2):223-32. Abstract
G
Gregory J, Kim H, Alonzo T, Gerbing R, Woods W, Weinstein H, Shepherd L, Schiffer C, Appelbaum F, Willman C et al..  2009.  Treatment of children with acute promyelocytic leukemia: results of the first North American Intergroup trial INT0129.. Pediatric blood & cancer. 53(6):1005-10. Abstract
R
Radich JP, Kopecky KJ, Appelbaum FR, Kamel-Reid S, Stock W, Malnassy G, Paietta E, Wadleigh M, Larson RA, Emanuel P et al..  2012.  A randomized trial of dasatinib 100 mg vs imatinib 400 mg in newly diagnosed chronic phase chromic myeloid leukemia.. Blood. Abstract